Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
3 hedge funds and large institutions have $7.45M invested in Hepion Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
200% more funds holding
Funds holding: 1 → 3 (+2)
136% more capital invested
Capital invested by funds: $3.16M → $7.45M (+$4.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$2.36M |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
+$2.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
-$76K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$61K |
| 3 |
CC
Callan Capital
La Jolla,
California
|
-$52K |
HEPA Hedge Fund Activity: Q3 2015 in Review
3 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2015, worth a combined $7.45M — up 136% from $3.16M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HEPA positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $2.36M. The largest seller was Eidelman Virant Capital, cutting an estimated $76K.
- 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2015, up from 1 in Q2 2015.
- Funds reported $7.45M of Hepion Pharmaceuticals stock for Q3 2015, up 136% quarter-over-quarter.
- 2 funds opened new Hepion Pharmaceuticals positions in Q3 2015 and 0 closed out, a net change of +2 holders.
- The largest Hepion Pharmaceuticals buyer in Q3 2015 was EAM Investors, an estimated $2.36M added.
- The largest Hepion Pharmaceuticals seller in Q3 2015 was Eidelman Virant Capital, an estimated $76K sold.
Based on aggregated 13F filings for Q3 2015.